We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Low-Volume Aldosterone Immunoassay Validated for Small Samples

By LabMedica International staff writers
Posted on 26 Sep 2017
Heart failure is a severe cardiovascular disease in adults and children and is characterized by structural or functional abnormalities of the heart. More...
Heart failure leads to an inappropriate blood circulation and subsequently to an undersupply of metabolizing tissues with oxygen and nutrients.

The humoral parameter aldosterone is part of the renin-angiotensin-aldosterone system (RAAS), which plays a major role in the body's salt and water balance. In clinical settings, serum aldosterone is recommended as a screening and diagnosis parameter for primary aldosteronism in high-risk patients.

Scientists at the Heinrich-Heine-University Düsseldorf (Germany) developed and validated a bioanalytical assay for the determination of aldosterone concentrations in small sample volumes. An immunoassay was developed based on a commercially available aldosterone enzyme-linked immunosorbent assay (ELISA) kit. Serum samples were donated by healthy volunteers. The optical density was measured using the absorbance reader infinite F50.

The investigators reported that the assay with a range 31.3 pg/mL to 1,000 pg/mL (86.9 pmol/L to 2,775 pmol/L) was characterized by a between-run accuracy from − 3.8% to − 0.8% and a between-run imprecision ranging from 4.9% to 8.9% (coefficient of variation). For within-run accuracy, the relative error was between − 11.1% and + 9.0%, while within-run imprecision ranged from 1.2% to 11.8% (CV). For parallelism and dilutional linearity, the relative error of back-calculated concentrations varied from − 14.1% to + 8.4% and from − 7.4% to + 10.5%, respectively. No impact of hemolysis on accurate sample determinations was observed.

The authors concluded that their present immunoassay is compliant with current bioanalytical guidelines of the European Medicines Agency (EMA) and allows accurate and precise aldosterone determinations in 40 µL serum. As the assay runs with low-volume samples, it is especially valuable for pediatric investigations, but is not limited to this population. The study was published originally published online on July 27, 2017, in the journal Practical Laboratory Medicine.

Related Links:
Heinrich-Heine-University Düsseldorf



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automatic CLIA Analyzer
Shine i6000
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: The model combines digitized tumor histopathology, clinical variables, and a 42-gene molecular panel using AI to generate a unified recurrence risk prediction (Image Credit: Shutterstock)

Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing

Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.